Rehmann Capital Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rehmann Capital Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$896	Hold	7	–	–	﹤0.01%	1573
2019 Q2	$997	Hold	7	–	–	﹤0.01%	1927
2019 Q1	$1K	Sell	7 -26	-79%	-$3.39K	﹤0.01%	1932
2018 Q4	$4.09K	Buy	33 +7	+27%	+$1.04K	﹤0.01%	1301
2018 Q3	$4.37K	Buy	26 +9	+53%	+$1.55K	﹤0.01%	1589
2018 Q2	$2.93K	Buy	+17	New	+$2.78K	﹤0.01%	1688
2016 Q1	–	Sell	-1,636	Closed	-$230K	–	382
2015 Q4	$230K	Buy	+1,636	New	+$227K	0.05%	296

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rehmann Capital Advisory Group's JAZZ Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q3 2019 at 7 shares worth $896. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Rehmann Capital Advisory Group first reported a position in JAZZ in Q4 2015 and has held it in 7 quarters since. The position peaked at $230K in Q4 2015. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

Rehmann Capital Advisory Group held 7 shares of Jazz Pharmaceuticals worth $896 as of Q3 2019.
Rehmann Capital Advisory Group left its Jazz Pharmaceuticals share count unchanged in Q3 2019.
Jazz Pharmaceuticals made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1573 holding.
Rehmann Capital Advisory Group first reported a position in Jazz Pharmaceuticals in Q4 2015 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Jazz Pharmaceuticals position peaked at $230K in Q4 2015.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.